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Abstract: Inflammasomes are supramolecular protein complexes implicated in the detection of pathogens or danger-associated
molecules and are responsible for mounting the first line of innate immune response to counteract these signals and restore tissue
homeostasis. Among different inflammasomes identified so far, NLRP3 is of main interest since mutations in Nlrp3 gene are associated
with autoinflammatory diseases such as Muckle–Wells syndrome, neonatal onset multisystem inflammatory disease, and familial cold
urticaria/autoinflammatory syndrome. On the other hand, whereas other inflammasomes are mainly detectors of specific molecular
motifs, NLRP3 is acting as a general sensor of cellular perturbations including potassium efflux, lysosomal damage, and ROS production.
Besides this central role of NLRP3 in inflammation, recent publications show that the NLRP3 inflammasome is also involved in the
physiopathology of several neurological disorders including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. This review
gives an overview of the established functions of the NLRP3 inflammasome in mediating inflammation in macrophages and describes
its recently discovered roles in neurological disorders in promoting neuroinflammation, as well as modulating key proteins mediating
the disorders. Finally, we discuss the targeting of NLRP3 in neurological diseases and present some examples of NLRP3 inhibitors that
could be used in neurological disorder treatments.
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1. Introduction
1.1. The NLRP3 inflammasome
Inflammasomes are cytosolic multiprotein complexes
mainly expressed in immune cells and are responsible for
the detection and elimination of pathogens or pathogenassociated molecules as well as danger-associated molecular
patterns (Martinon et al., 2002). Several inflammasomes
activated by specific ligands have been described so far:
NLRP3, Pyrin, NLRP1, NLRC4, and AIM2 are induced,
among other stimulants, by ATP (Mariathasan et al., 2006),
Clostridium difficile (Xu et al., 2014), muramyl dipeptide
(Hsu et al., 2008), bacterial flagellin (Sutterwala et al.,
2007), and polydA:dT (Hornung et al., 2009), respectively.
Induction of these inflammasomes triggers the
proteolytic cleavage of caspase-1 that in turn cleaves the
proforms of IL-1β, IL-18, and gasdermin D into their
active mature forms. The mature N-terminal domain
of gasdermin D is inserted into the plasma membrane
to form pores and triggers a specific immunological cell
death called pyroptosis (Shi et al., 2015; Liu et al., 2016).
Mature IL-1β is then secreted from the cells through
these gasdermin D pores into the extracellular matrix to

recruit other immune cells to the infection site in order
to eliminate the trigger and reestablish tissue homeostasis
(He et al., 2015; Jorgensen et al., 2016).
NLRP3 protein is a member of NOD-like receptors
(NLRs) composed of an N-terminal pyrin providing a
homotypic protein/protein interaction, a central NACHT
responsible for oligomerization, and a C-terminal leucine
rich repeat (LRR) domain which may act as a “sensor” and
inhibit NLRP3 by its folding on the complex. Upon its
stimulation by ion flux triggering molecules such as ATP
and nigericin or monosodium urate crystals (MSU), NLRP3
forms a supramolecular complex with the adaptor protein
ASC that in turn recruits the effector protease caspase-1
to constitute a multiprotein complex, otherwise known
as “specks”, that serves as a platform for the nucleation of
the inflammasome (Sehlik et al., 2003). However, unlike
other known inflammasomes, the NLRP3 inflammasome
requires two signals to be induced: the priming and the
activation (Figure 1). First of all, cells need to be primed
by the activation of membrane-bound toll-like receptors
(TLRs) to induce the expression of the inflammasome
components NLRP3, caspase-1, and pro-IL-1β through
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Figure 1. Activation mechanisms of the NLRP3 inflammasome. The NLRP3 inflammasome requires two
signals to be activated: the priming signal conferred by stimulation of TLRs by LPS and subsequent induction
of inflammasome components’ gene expression through the NFkB pathway and secondly, an activatory
signal that triggers the oligomerization of the complex NLRP3 with ASC and Caspase-1; that could be
either ROS production by the mitochondria induced by Imiquimod, potassium efflux resulting from ATP or
Nigericin stimulation or lysosomal rupture triggered by phagocytosed crystals. The NLRP3 inflammasome
is also indirectly activated through the noncanonical inflammasome formed by caspase-4/5 that senses
lipopolysaccharide from gram-negative bacteria. LPS: Lipopolysaccharide; TLR: Toll-like receptor; ROS:
Recative oxygen species; ATP: Adenosine triphosphate

the NFκB pathway or type I IFN pathway, in the case of
endosomal TLRs (Bauernfeind et al., 2009). This priming
step is generally induced through the stimulation of TLR4
by lipopolysaccharide (LPS). This ligand triggers a cascade
of signaling that results in the induction of inflammasome
components’ gene expression.
Once primed, a second signal is required to fully
activate the complex. To date, three different events have
been found to provide this signal: lysosomal destabilization
and rupture (Hornung et al., 2008), mitochondrial reactive
oxygen species (ROS) production (Zhou et al., 2011), and
decrease of intracellular potassium concentration (Petrilli
et al., 2007; Muñoz-Planillo et al., 2013). When crystals
such as monosodium urate or aluminum are phagocytosed
by cells, because of their size and their structure, they
induce lysosomal homeostasis dysregulation, which
may result in lysosomal rupture. The release of several
components that are supposed to be confined into these
organelles, for instance cathepsin G, activates the NLRP3
inflammasome. Similarly, dysregulation of mitochondrial
metabolic activity through the impairment of voltagedependent anion channel is sensed by NLRP3 that directly
binds to cardiolipin that is a lipid component of the inner
membrane of mitochondria (Zhou et al., 2011; Iyer et al.,
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2013). Finally, changes in ionic (Ca++, K+) flux triggered
by the stimulation of P2RX7 receptors by nigericin or ATP
cause the efflux of potassium that is sensed by NLRP3, that
gets activated.
Although the activation of the NLRP3 inflammasome
is tightly regulated at different levels, mutations in the
Nlrp3 gene resulting in overactivation of the complex
were identified in patients with autoinflammatory diseases
(Aganna et al., 2002). For this reason, to cure these diseases
NLRP3 inflammasome targeting strategies were developed.
Among the most efficient is Anakinra treatment; Anakinra
is a molecule that antagonizes the IL-1 receptor, thus
blocking IL-1 signaling triggered by excessive IL-1β
secretion was observed in these patients (Hawkins et al.,
2004). Another possible treatment is the use of the specific
NLRP3 inhibitor MCC950 (Coll et al., 2015). In a mouse
model of Muckle–Wells syndrome induced by Nlrp3
mutation, administration of MCC950 increased mice’s
survival and diminished IL-18 levels in the serum (Coll et
al., 2015). However, contradictory findings showing that
MCC950 is only effective on the inhibition of WT NLRP3
also exist (Wall et al., 2019 BioRxiv). Nonetheless, as it will
be described below, inhibition of NLRP3 by MCC950 in
pathological conditions involving nonmutant NLRP3 is
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still under investigation in neurological disorders and will
probably enter clinical trials soon. Despite these extensive
studies on NLRP3, our knowledge on this inflammasome
is mainly limited with its functions in macrophages. In
fact, recent publications suggest a new role for NLRP3 in
the context of neurological disorders.
1.2. Neuroinflammation
Microglial cells are the immune cells of the central nervous
system that are considered tissue-resident macrophages
responsible for preserving brain homeostasis to provide
an adequate environment for the neurons to function.
Microglial cells express many pathogen recognition
receptors, including NLRP3, that allow their activation
in response to pathogen infiltration through the blood
brain barrier or in the case of injuries. Microglia are highly
active cells that survey the brain and when activated are
able to phagocytose and eliminate abnormal protein
deposits in the brain seen in some neurological diseases
and to secrete chemokines to increase the blood brain
barrier permeability promoting the recruitment of other
lymphocytes to the infection/injury site (Nimmerjahn et
al., 2005). However, the protective neuroinflammation
triggered by microglial cells can become detrimental for
the host in certain pathological conditions. Pathological
neuroinflammation is caused by abnormally high
cytokine/chemokine secretion due to an excessive amount
of stimulants (Alzheimer’s and Parkinson’s diseases),

infection (meningitis) or physical or mechanical injuries
(traumatic brain injuries), and vascular occlusions
resulting in an excessive inflammasome activation,
dysregulation of blood brain barrier (BBB) permeability or
BBB breakdown, and increased infiltration of peripheral
immune cells. In the following section, different examples
of neurological disorders will be given and the role of
the NLRP3 inflammasome in the development of these
diseases will be presented.
2. NLRP3 in neurological diseases
Neuroinflammation is a driving force of the
physiopathology of several neurological diseases. These
patients present in their plasma or cerebrospinal fluid an
increased level of IL-1 family cytokines IL-1β and IL-18
that are controlled by inflammasomes. The involvement
of the NLRP3 inflammasome in Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis, and traumatic brain
injury will be presented (Table; Figure 2).
2.1. Alzheimer’s disease
Alzheimer’s disease (AD) is a sporadic late onset
neuropathology characterized by the accumulation of an
insoluble form of amyloid β (Aβ) proteins in the brain
(Masters et al., 2015). Aβ is generated by the cleavage
of amyloid precursor protein (APP) at different sites
by Presenitin-1 (PS1) and Presenitin-2 (PS2) enzymes
from the secretase family. Whereas cleaved forms of

Table. The NLRP3 inflammasome in neurological disorders.

Alzheimer disease

Species

Molecular mechanisms of NLRP3 activation

References

Human

Elevated IL-1β levels in the cerebrospinal fluid of AD patients.

Halle et al., 2008

Mouse

Human
Parkinson disease
Mouse

Aβ is phagocytosed by mouse microglial cells and induce lysosomal rupture
and cathepsin B release.
In APP/PS1 model of AD, depletion of Nlrp3 improves memory, decreased
IL-1β levels and reduced Aβ deposits.
ASC specks secreted by Nlrp3-activated microglia promotes the
oligomerization of Aβ and increase plaque formation.
Tau-dependent neurofibrillary tangles formation was reduced by ASC
targeting.
α-synuclein is cleaved by caspase-1 and in a neuronal cell line α-synuclein
aggregation is prevented by caspase-1 inhibition.
Costaining of α-synuclein and caspase-1 in the postmortem brain of PD
patients.
Fyn and CD36-dependent α-synuclein phagocytosis and ROS production
leading to NLRP3 activation.
In MPTP-induced mouse model of PD, depletion of Nlrp3 or blocking IL1β
receptor ameliorated the PD phenotype.

Halle et al., 2008
Heneka et al., 2013
Venegas et al, 2017
Stancu et al., 2019
Wang et al., 2016
Wang et al., 2016
Panicker et al., 2019
Lee et al., 2019

Traumatic brain injury Mouse

Increased caspase-1 and IL-1β cleavage and secretion.

Xu et al., 2018

Multiple sclerosis

In experimental autoimmune encephalomyelitis (EAE) improvement of
phenotype by Nlrp3 depletion.

Gris et al., 2010

Mouse
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Figure 2. The NLRP3 inflammasome in neurological disorders and novel inhibitor drugs. The NLRP3
inflammasome is activated in reponse to several neurological disorder-triggering molecules. While
β-amyloid and α-synuclein, implicated in Alzheimer’s and Parkinson’s disorders respectively, induce
lysosomal rupture and Cathepsin B-dependent NLRP3 inflammasome activation; danger associated
molecular patterns (or DAMPs) released during traumatic brain injury trigger ROS-dependent NLRP3
inflammasome activation. Different inhibitory molecules of the NLRP3 inflammasome that resulted in
the improvement in the disease outcome are also shown.

Aβ are soluble and have short half-life in the brain of
healthy individuals through its degradation by specific
enzymes or phagocytosis by microglia; in AD patients, a
42 kDa insoluble form is predominant and accumulates
to form Aβ plaque deposits in the extracellular milieu.
This in turn triggers the accumulation of the tau protein
that leads to the formation of neurofibrillary tangles in
neurons. Altogether, these phenomena result in synaptic
loss, neuronal death, and dysregulated neurotransmitter
signaling (Masters et al., 2015).
Amyloid β proteins, the molecular hallmark of AD,
are phagocytized by microglia and induce the secretion of
IL-1β in cerebrospinal fluid of patients. Fibrillar but not
soluble Aβ was found to induce the NLRP3 inflammasome
in a mouse microglial cell line in a phagocytosis-dependent
manner (Halle et al., 2008). Phagocytized Aβ accumulated
in the lysosomes and triggered lysosomal destabilization
and rupture and cathepsin B release into the cytosol (Halle
et al., 2008), consistent with the fact that higher amount
of cathepsin B is found in Aβ plaques and cathepsin B
inhibition ameliorates AD. Lysosomal damage induced by
Aβ internalization triggered NLRP3 activation, ASC speck
formation, caspase-1 maturation, and IL-1β secretion.
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Another evidence for the involvement of the NLRP3
inflammasome in AD pathology comes from the studies of
AD-associated mutant APP/PS1 expressing mice that are
also Nlrp3 knocked out (APP/PS1/Nlrp3-/-; Heneka et al.,
2013). In fact, while Aβ accumulated in the brain of APP/
PS1 mice and triggered AD symptoms, impairment of the
Nlrp3 gene in these mice ameliorated their AD phenotype:
APP/PS1/Nlrp3-/- mice have decreased IL-1β levels in total
brain, absence of caspase-1 cleavage and improved memory
test. Moreover, depletion of Nlrp3 considerably reduced
the amount of Aβ plaque deposits in the brain of APP/
PS1/Nlrp3-/- compared to APP/PS1 mice and differentiated
microglia towards a M2 type antiinflammatory immune
response favoring tissue remodeling and Aβ clearance
(Heneka et al., 2013).
In addition, ASC specks formed in response to NLRP3
activation have some prionic activity as they are secreted
from the cells and induce the oligomerization of other
proteins (Franklin et al., 2014). Similarly, in AD, ASC
specks are secreted from microglia, bind to Aβ, increase
their oligomerization, and facilitate their propagation in
different areas of the brain (Venegas et al, 2017). Asc gene
knockout, antibody targeting, or mutation of pyrin domain
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of ASC responsible for oligomerization significantly
reduced Aβ deposit and ameliorated cognitive functions
of AD model of mice (Venegas et al., 2017).
Besides amyloid plaques, neurofibrillary tangles are
also observed in the brain of AD patients as a result of
tau protein accumulation. Tau protein was shown to
activate the NLRP3 inflammasome in microglia and its
oligomerization was exacerbated by ASC similar to Aβ
plaques (Stancu et al., 2019). Depletion of Asc or inhibition
of the NLRP3 inflammasome by MCC950 reduces tauinduced neurofibrillary tangle formation (Stancu et al.,
2019).
2.2. Parkinson’s disease
Parkinson’s disease (PD) is a neurological disease causing
the death of dopaminergic neurons thus impairing
the movement of patients. PD is characterized by the
accumulation of α-synuclein protein in the cytoplasm of
neurons (Poewe et al., 2017). α-synuclein is encoded by
the SNCA gene and is normally degraded by the ubiquitin/
proteasome or lysosomal autophagy system. However,
in Parkinson’s disease, mutations in critical players of
the lysosomal pathway such as LRRK2, GBA genes were
identified. α-synuclein forms protofibrils and then fibrils
that will finally constitute the major part of Lewis bodies
and cause neuron loss and dopamine deficiency. The signal
is amplified as dysregulation of the lysosomal pathway
leads to synuclein accumulation whereas these aggregates
in turn inhibit lysosomal pathway functioning (Poewe et
al., 2017).
Interestingly, activation of the NLRP3 inflammasome
in a neuronal cell line resulted in α-synuclein aggregation
that could be prevented by caspase-1 enzymatic activity
inhibition by using VX765 or knockdown using shRNA.
Caspase-1 was able to directly cleave α-synuclein at
Asp121 in in vitro experiments and this cleaved form was
more prone to aggregation than the others (Wang et al.,
2016). Indeed, Lewis bodies isolated from postmortem PD
patients showed costaining of caspase-1 and α-synuclein in
these structures suggesting an important role of caspase-1
in PD pathology (Wang et al., 2016). Similarly, uptake of
α-synuclein by microglia was mediated by Fyn and CD36
and led to NLRP3 inflammasome priming and activation
in these cells due to nuclear translocation of NFκb and to
mitochondrial malfunction resulting in reactive oxygen
species generation (Panicker et al., 2019).
Moreover, depletion of Nlrp3 protected from
dopaminergic neuron loss, and decreased microglia
recruitment and activation and resulted in a lower level
of IL-1β in a mouse model of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)-induced mouse model of
PD (Lee et al., 2019). Stimulation of primary microglia
cells with MPTP in vitro triggered NLRP3-dependent
caspase-1 and IL-1β maturation as well as increasing proIL-1β levels. MPTP induced neuroblastoma cell lines death

in a NLRP3-dependent manner and PD phenotype could
be reverted in MPTP-mice by IL-1β receptor antagonist
administration (Lee et al., 2019).
2.3. NLRP3 in other neurological disorders
NLRP3 is also implicated in other neurological conditions
such as multiple sclerosis and traumatic brain injury.
Multiple sclerosis is a chronic inflammatory disease
characterized by T cell reactivity to self that causes
demyelination of the neurons and appearance of brain
lesions. These lesions trigger the infiltration of immune cells
and the breakdown of the blood brain barrier in some cases
resulting in excessive inflammation in the brain (Filippi et
al., 2018). Extensive studies were performed in mice in a
model of experimental autoimmune encephalomyelitis
(EAE). Increased NLRP3 levels were observed in EAE
model and Nlrp3-/- showed less immune cell infiltration,
less demyelination and improved neurological scores.
NLRP3 was activated in multiple sclerosis and induced
the secretion of IL-1β as well as IL-18. IL-18 in turn
activates IFN-γ and IL-17 production thus eliciting a Th1
and Th17 immune response that was impaired in Nlrp3-/mice (Gris et al., 2010). These data suggest that NLRP3 not
only has a role in the innate immune response mediated
neuroinflammation but also modulates adaptive response
by regulating T-cells. On the other hand, physical and/
or mechanical damage in the brain result in traumatic
brain injury (Blennow et al., 2016). Danger-associated
molecular patterns released following these injuries lead
to NLRP3 activation and neuroinflammation. Increased
NLRP3 and cleaved caspase-1 and IL-1β levels were found
in mouse models of traumatic brain injuries suggesting an
important role for NLRP3 inflammasome (Xu et al., 2018).
3. Other inflammasomes in neurological diseases
Besides the NLRP3 inflammasome, NLRC4 inflammasome
was also shown to be implicated in neurological diseases.
Lysophosphatidylcholine (LPC) that accumulates in
multiple sclerosis and Alzheimer’s disease (Farooqui
et al., 2006) was shown to activate both the NLRP3 and
NLRC4 inflammasomes and to result in the increased IL1β secretion seen in these patients (Freeman et al., 2017).
Moreover, the NLRC4 and NLRP3 inflammasomes were
also found to play a role in glioma that is a tumor of the
central nervous system. Whereas both NLRP3 and NLRC4
were expressed in the brain and colocalized with caspase-1,
only NLRC4’s expression was elevated in glioma samples
and correlated with poor diagnostic of these patients (Lim
et al., 2019).
Not only NLRP3 and NLRC4 but also NLRP1
inflammasome were shown to have a role in neurological
diseases. Polymorphisms in the NLRP1 gene are associated
with Alzheimer’s disease (Pontillo et al., 2012) and
multiple sclerosis (Maver et al., 2017), the latter resulting
in an increase of IL-1β expression in peripheral blood
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mononuclear cells isolated from patients carrying these
polymorphisms. Moreover, increased NLRP1 expression
was measured in monocytes isolated from Alzheimer’s
disease patients upon LPS and amyloid beta stimulation
(Saresella et al., 2016).
Finally, the DNA sensing AIM2 inflammasome was
shown to have a deleterious role in experimentally induced
ischemic brain injury by middle cerebral artery occlusion
since knockout mice presented improved neurological
outcomes and reduced inflammation (Denes et al., 2015).
AIM2 levels were upregulated in spinal cord ischemia
reperfusion after traumatic injury and targeting AIM2
prevented neuronal pyroptosis (Li et al., 2019). Altogether,
these suggest that several inflammasomes, mostly in
cooperation with NLRP3 or occasionally alone, have an
important role in the physiopathology of neurological
disorders. However, for most of them, the stimulant that
activates these inflammasomes remains unclear.
4. Inhibiting NLRP3 in neurological diseases
4.1. MCC950
Being of central interest due to its involvement in
autoinflammatory diseases, extensive searches have been
conducted to identify an NLRP3 inflammasome inhibitor
(Figure 2). The diarylsulfonylurea compound MCC950/
Cytokine release Inhibitory Drug 3 (CRID3) is a small
molecule firstly identified to inhibit IL-1β secretion.
Further studies demonstrated that MCC950 interferes
with ASC oligomerization, caspase-1 cleavage, IL-1β
secretion and pyroptosis (measured by LDH release) in
response to NLRP3 stimulation, with no effect on other
inflammasomes or caspase-11-induced cell death (Coll et
al., 2015). MCC950 is a reversible inhibitor that directly
binds to both active and inactive NLRP3’s NACHT domain
responsible for oligomerization and inhibits the hydrolysis
of ATP to ADP necessary for oligomerization (Coll et
al., 2019). MCC950 was shown to maintain NLRP3 in its
closed inactive state upon its binding preventing then its
oligomerization and activation (Tapia-Abellán et al., 2019).
Several in vivo experiments were performed to test the
efficacy of MCC950 in neurological diseases. Treatment
of mice with MCC950 ameliorated their clinical score of
mice and reduced in the number of cells producing IFN-γ
and IL-17 in a mouse model of EAE (Coll et al., 2015).
In several other studies, MCC950 was found to efficiently
repress the NLRP3 inflammasome induced by traumatic
brain injury and decrease the neurological severity score
in mice model of unilateral cortical impact, controlled
cortical injury impact and isofluorane-induced traumatic
brain injuries (Fan et al., 2018; Ismael et al., 2018; Xu et
al., 2018).
In a mouse model of APP/PS1 mice, besides inhibiting
NLRP3-dependent symptoms seen in Alzheimer’s
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disease, MCC950 also increased the uptake of β-amyloid
plaques and ameliorated neurological outcomes by
inducing their clearance (Dempsey et al., 2017). Finally,
inhibition of NLRP3 by MCC950 was also investigated
in the context of Parkinson’s disease. NLRP3 and ASC
levels were upregulated and NLRP3, ASC, and cleaved
caspase-1 colocalized with Iba the marker for activated
glia in postmortem brain sections of PD patients as
well as two mouse models of PD triggered by either
6-hydroxydopamine or α-synuclein performed fibril
injections (Gordon et al., 2018). Oral administration
of MCC950 efficiently blocked cleaved caspase-1
generation in the brain in vivo in α-synuclein performed
fibril induced-, 6-hydroxydopamine induced-PD, and
MitoPark mouse model of PD (involving the knockout
of Tfam gene and resulting in mitochondrial respiratory
chain deficiency). MCC950 also decreased dopaminergic
neuron death 6-hydroxydopamine induced-PD model
and α-synuclein performed fibril-PD. Moreover, chronic
administration of MCC950 decreased accumulation of
α-synuclein without affecting protein levels. Altogether,
these findings make the NLRP3 inhibitor MCC950 a good
therapeutic for Parkinson’s disease (Gordon et al., 2018).
MCC950 is predicted to enter human clinical trials in
2020.
4.2. Caspase-1 inhibition
Caspase-1 is a central player in the activation of the NLRP3
inflammasome. It is the effector that activates IL-1β/IL18 and gasdermin D that mediates the immunological
outcomes. Before being found to be a component of
inflammasomes, caspase-1 was identified as “the interleukin
1- converting enzyme” and many inhibitor molecules have
been designed and tested to inhibit caspase-1’s activity
(Kostura et al., 1989). In the context of neurological
diseases, caspase-1 has a deleterious role in the disease
progression since caspase-1 knockout mice were protected
from clinical hallmarks of Alzheimer’s disease (Flores et
al., 2018). Administration of a reversible small caspase-1
specific inhibitor VX-765 in Alzheimer’s disease model
of mice showed improvement of mice clinical behaviors,
resulted in decrease in hippocampal and cortical IL-1β
levels and prevented amyloid beta deposit (Flores et al.,
2018). VX-765 also called Belnacasan is an orally active
form of VRT-043198 and although being promising in
the eradication of Alzheimer’s disease manifestations, the
necessity of continuous administration of VX-765 and
treatment at very early stages of the disease, VX-765 seems
to stay as a proof-of-concept of caspase-1’s implication in
Alzheimer’s disease.
VX-765 was also used in the inhibition of Caspase-1 in
a mouse model of MS. Increased IL-1β, IL-18, caspase-1,
and gasdermin D levels and MS lesions positive for
gasdermin D staining were found in postmortem samples
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of MS patients and EAE model (McKenzie et al., 2018).
Treatment of EAE mice with caspase-1 inhibitor VX765 decreased upregulated transcript levels, reduced
gasdermin D stainings, and restored microglia density
suggesting an improvement of the disease (McKenzie et
al., 2018). Even if not frequently involved, the presence
of caspase-1-independent pathways leading to IL-1β
maturation and the possibility of triggering gasdermin
D-mediated pyroptosis by caspase-11, force researchers to
find an alternative way of targeting NLRP3.
4.3. A20
The priming by NFκB pathway is an essential step in the
activation of the NLRP3 inflammasome. The A20 protein
negatively regulates this pathway by acting on its players
through the modulation of the ubiquitination resulting in
either the destabilization of protein/protein interactions or
the degradation of these proteins (Coornaert et al., 2009).
Mutations in Tnfaip3 gene encoding for A20 were associated
with increased susceptibility to autoinflammatory
diseases (Ma et al., 2012). A20-deficient mice developed
spontaneous neuroinflammation and promoted axon
injury (Guedes et al., 2014). Interestingly, A20 is highly
expressed in developing and mature adult nervous system
(Voet et al., 2018). As full knockout of A20 led to massive
inflammation and organ failure, conditional A20 KO mice
were generated to investigate the effect of A20 in the brain.
The number of microglia was increased in the brain and
cerebrospinal fluid of conditional knockout mice and
proinflammatory genes were upregulated in these cells.
As a result, A20 KO mice showed poor cognitive function.
A20 was also protective against LPS injections and EAE
model of MS. A20 mediated its protective effect through
the inhibition of the NLRP3 inflammasome as Nlrp3/A20
double knockout mice showed a better clinical score than
A20 knockout mice in EAE (Voet et al., 2018).
4.4. Inhibitory NLR proteins
NOD-like receptors (NLRs) are a family of cytosolic
proteins that besides forming inflammasome complex
(such as NLRP1, NLRP3, NLRP6, NLRC4), can also have
antiinflammatory roles. NLRP10, NLRX1, and NLRC3
proteins belong to the last group. These proteins were
found to negatively regulate NFκB pathway as well as
NLRP3 inflammasome itself. NLRX1 was first identified
as an inhibitor of the NFκB pathway (Allen et al., 2011)
and a modulator of the RIG-I/MAVS pathway during viral
infections (Allen et al., 2011; Moore et al., 2008). Besides
this antiinflammatory role, NLRX1 is also neuroprotective
in mouse model of multiple sclerosis (Eitas et al., 2014).
Nlrx1-/- mice presented enhanced limb paralysis, more
proinflammatory cytokine expression in the spinal cord
tissue, increased demyelination and higher immune cell
infiltration in the brain suggesting that Nlrx1 is important
to control inflammation in the central nervous system and

preserve tissue homeostasis in multiple sclerosis (Eitas
et al., 2014). Similarly, in a mouse model of controlled
cortical impact traumatic brain injury, Nlrx1-deficient
mice showed higher brain lesions, worse clinical score,
increased inflammation, and higher microglia recruitment
and activation (Theus et al., 2017). Moreover, expression
analysis in patients with aneurysm revealed that NLRX1
expression is downregulated compared to healthy controls
(Theus et al., 2017). In a molecular level, NLRX1 protein
regulates glutamate homeostasis, the principal neurostimulant amino acid in the central nervous system
(Mahmoud et al., 2019). Accumulation of glutamate in
the extracellular milieu is toxic for the brain. NLRX1
increases the uptake of glutamate into the astrocyte and
inhibits its exocytosis. Although direct inhibition of the
NLRP3 inflammasome by NLRX1 was not shown in the
brain, it could be a good target since MAVS facilitates
oligomerization of NLRP3 and its activation (Park et al.,
2013). For instance, in an acute myocardial ischemia,
NLRX1 was shown to inhibit NLRP3 inflammasome
activation through MAVS expression downregulation (Li
et al., 2016).
NLRC3 protein is a CARD domain containing
member of the NLR family and was described to have an
inhibitory role on NFκB pathway by targeting TRAF6 to
ubiquitination (Conti et al., 2009; Schneider et al., 2012).
Modulation of the NFκB pathway by NLRC3 was shown
to suppress CD4+ T cell activation, thus facilitating
Mycobacterium tuberculosis escape from the immune
system (Hu et al., 2018) or increasing susceptibility to
lymphocytic choriomeningitis virus infection (Uchimura
et al., 2018). Besides NFκB, NLRC3 also modulates the
STING pathway by disrupting STING/TBK1 interaction
(Zhang et al., 2014) through direct STING binding and
this interaction is disrupted through the binding of viral
DNA to the LRR domain of NLRC3 that will liberate
STING and activate type I interferon production (Li et al.,
2019). Moreover, NLRC3 was found to inhibit specifically
NLRP3 inflammasome activation by interfering with
the assembly of ASC with caspase-1 thus reducing ASC
speck formation caspase-1 maturation of (Eren et al.,
2017). Furthermore, in zebrafish, NLRC3 homolog called
Nlrc3-like was required for controlling inflammation in
the brain. Mutation in Nlrc3-like resulted in increased
IL-1β expression in the glia and increased neuronal cell
death (Wang et al., 2019). These phenotypes could be
reverted by depletion of Asc or inactivation of gasdermin
D homolog Gsdmea by morpholino oligos suggesting
that Nlrc3-like is an inflammasome inhibitor in zebrafish
microglia (Wang et al., 2019). Nlrc3-like was also required
for normal microglia development in zebrafish brain
(Shiau et al., 2013). In the presence of mutant Nlrc3like protein, primitive macrophages could not populate
the brain and accumulated in the yolk sac with signs of
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activated macrophages including increased expression
of proinflammatory cytokines IL-1β and IL-18 among
others. Together with abnormal infiltration of neutrophils
in the brain, Nlrc3-like mutation resulted in systemic
inflammation. Expression of WT Nlrc3-like rescued the
phenotype and molecular analysis revealed that Nlrc3-like
directly interacts with Asc thus impairing inflammasome
activation (Shiau et al., 2013). The role of Nlrc3 in
microglia inflammation or development is not confirmed
in mice yet but high expression of NLRC3 in brain and
different nervous cells suggest that it may have a similar
role in mice and humans. Therefore, expressing NLRC3
could be a good strategy to target both NFκB pathway and
NLRP3 inflammasome. Especially, since ASC specks are
important vectors of most of the neuropathologies, the
ability of NLRC3 to disrupt ASC oligomerization may be
benefic for the patients.
5. Conclusions
Up to now, NLRP3 inflammasome research was limited
to macrophages and especially to mouse bone marrowderived or human peripheral blood mononuclear cellderived macrophages or human leukemia cell line THP-1.
Recent findings clearly show that NLRP3 inflammasome
components are expressed not only in a variety of other
cell types including neutrophils, epithelial and endothelial
cells but also in some tissue-resident macrophages, such
as microglia in the brain, Kupffer cells in the liver, and
Langerhans cells in the skin.
Investigation of NLRP3’s role in several neurological
disorders reveals that excessive inflammatory signature
observed in these pathologies is most often due to
increased IL-1β levels in the brain and cerebrospinal
fluid of patients. Abnormally folded protein aggregates
responsible for the neurodegeneration were either directly
generated by inflammasome components, as in the case
of the cleavage of α-synuclein by caspase-1 in Parkinson’s
disease, or constituted a trigger for NLRP3 activation
such as β-amyloid in Alzheimer’s disease. Targeting of
the NLRP3 inflammasome at different levels resulted in
the amelioration of the disease progression. Interfering
with NLRP3 priming by targeting A20 protein, blocking
caspase-1 with VX-765 or inhibition of NLRP3 directly
with MCC950 gave very promising results. Especially,

specific inhibition of NLRP3 by MCC950 by daily oral
administration of this molecule allowed disease regression
in all mice models of Parkinson’s disease tested.
Although the majority of studies on neurodegenerative
diseases and NLRP3 inflammasome show that NLRP3
inhibition is beneficial for the regression of the disease
symptoms, two studies at least suggest that outcomes
of NLRP3 activation may have a protective role on the
symptoms. For instance, deletion of IL-18, a cytokine that
is maturated by caspase-1 cleavage and secreted following
NLRP3 activation, increased mortality of APP/PS1 mice
as a result of increased deposition of amyloid plaques
(Tzeng et al., 2018). A similar protective role of IL-18 was
also observed in cerebral ataxia (Andoh et al., 2008). IL-18
is an important regulator of T cell and natural killer cell
response. It is clear that neurodegenerative pathologies are
quite complex disorders and may involve the participation
of both innate and adaptive immune system. Whether
neuroinflammation is beneficial or not for the patients
is probably determined by several factors including the
disease type and the severity of the pathology.
Another major outcome of the NLRP3 inflammasome
activation is the induction of a form of cell death called
pyroptosis. Most of the studies are mainly based on
caspase-1 and IL-1β levels in patients or mouse model of
the diseases. Only in few of them, the role of gasdermin
D was studied. Gasdermin D staining in lesions of brain
tissues was shown or gasdermin D was found to be
responsible for the neuronal death observed. However,
other publications suggest that although IL-1 is important,
pyroptosis does not have a role in the development of
the pathology also exist. Thus, the effect of pyroptosis in
neurological disorders has to be further confirmed and
if implicated, targeting of gasdermin D in these diseases
should also be considered. The relationship between
NLRP3 and neurological disorders is an emerging field
that needs further investigation. Nonetheless, the targeting
of NLRP3 in different neuropathologies is obviously
promising.
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